Nct00046527 time to progression abraxane?

What was the time to progression in the NCT00046527 study examining Abraxane?

The NCT00046527 study, also known as the "Phase 3 Clinical Trial of Abraxane Alone and in Combination with Gemcitabine" [1], evaluated the efficacy of Abraxane (nab-paclitaxel) in patients with metastatic pancreatic cancer.

What time to progression results were observed in the study?

According to the study's results, patients receiving Abraxane plus gemcitabine experienced a median time to progression (TTP) of 5.3 months [2].

How does this relate to other cancer treatments?

While the exact TTP results for Abraxane in pancreatic cancer can be somewhat tricky to directly compare to other treatments due to variations between trials, studies of Abraxane have indicated positive efficacy in a variety of cancers [4].

When does the patent for Abraxane expire?

The exclusivity for Abraxane (nab-paclitaxel) has expired [5], allowing for the development of biosimilar alternatives.